特集: 調査項目の変更・追加が可能なセミカスタムオーダー型の調査レポート(Lucintel社)はこちら

特集 : 国別の市場調査レポートをお探しの方はこちら

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

逆流性食道炎(胃食道逆流症):パイプライン分析

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2020

発行 Global Markets Direct 商品コード 232845
出版日 ページ情報 英文 107 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.13円で換算しております。
逆流性食道炎(胃食道逆流症):パイプライン分析 Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2020
出版日: 2020年01月14日 ページ情報: 英文 107 Pages
概要

胃液が食道に逆流する状態を胃食道逆流症(GERD)と呼び、悪心、胸やけ、嘔吐といった症状があります。下部食道括約筋(LES)の誤った開閉を引き起こす過食や、肥満、妊娠、脂っぽい食べ物、一部の医薬品などの素因があります。

当レポートでは、世界における逆流性食道炎(胃食道逆流症)治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

逆流性食道炎(胃食道逆流症)の概要

治療薬の開発

  • 逆流性食道炎(胃食道逆流症)向けパイプライン製品:概要
  • 逆流性食道炎(胃食道逆流症)向けパイプライン製品:比較分析

逆流性食道炎(胃食道逆流症):開発中の治療薬:企業別

逆流性食道炎(胃食道逆流症):開発中の治療薬:大学・研究機関別

逆流性食道炎(胃食道逆流症):パイプライン製品の概況

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

逆流性食道炎(胃食道逆流症):開発中の製品:企業別

逆流性食道炎(胃食道逆流症):開発中の製品:大学・研究機関別

逆流性食道炎(胃食道逆流症):治療薬開発に従事している企業

  • Ahn-Gook Pharmaceutical Co., Ltd.
  • aRigen Pharmaceuticals, Inc.
  • Cempra, Inc.
  • Daewoong Pharmaceutical Co., Ltd.
  • エーザイ
  • Ironwood Pharmaceuticals, Inc.
  • Johnson & Johnson
  • RaQualia Pharma Inc.
  • Shire Plc
  • Sucampo Pharmaceuticals, Inc.
  • Vecta Ltd.
  • Wockhardt Limited
  • Yuhan Corporation
  • Yuyu Pharma, Inc.

逆流性食道炎(胃食道逆流症):治療薬の評価

  • 単剤治療薬
  • コンビネーション製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • ARH-1029
  • cobiprostone
  • DWJ-1367
  • E-3710
  • エソメプラゾールマグネシウム
  • G-17DT
  • IW-3718
  • JNJ-26070109
  • オメプラゾール
  • パントプラゾール
  • RQ-00000004
  • RQ-00000774
  • 消化性潰瘍治療薬
  • GERDおよび糖尿病性胃不全まひ向けモチリン受容体阻害剤
  • 消化器疾患向けプロトンポンプ阻害剤
  • SSP-002358
  • テナトプラゾール
  • YH-4808
  • YY-DXR
    • 製品概要
    • 作用機序
    • R&Dの進捗

最新のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発マイルストーン

  • 注目のニュース・プレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ahn-Gook Pharmaceutical Co Ltd, H1 2020
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by CalyGene Biotechnology Inc, H1 2020
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, H1 2020
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products, H1 2020
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products, H1 2020 (Contd..1), H1 2020

List of Figures

  • Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
目次
Product Code: GMDHC11876IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2020, provides an overview of the Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline landscape.

When the liquid content of the stomach refluxes into the oesophagus, that condition is called Gastroesophageal reflux disease (GERD). It is a chronic condition. The symptoms of GERD are nausea, heartburn and vomiting. The predisposing factors include eating large meals, which can cause the Lower Esophageal Sphincter (LES) to open inappropriately, as well as obesity, pregnancy, greasy food and certain drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 8, 7, 7, 3 and 4 respectively.

Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction

  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Overview
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Development
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Assessment
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Companies Involved in Therapeutics Development
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Drug Profiles
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Product Development Milestones
  • Appendix